The private equity fund EQT has sold Ellab to Novo Holding A/S.
Ellab provides validation and monitoring solutions and related services to the world’s leading biotech and pharmaceutical businesses. The solutions are used to measure and document critical parameters such as temperature, pressure and CO2 in classified production environments. During EQT’s ownership, Ellab has tripled its revenue, EBITDA and the number of employees and has completed 15 add-on acquisitions.
EQT is one of the world’s leading private equity funds with assets of EUR 119bn under management. In its acquisitions, EQT focuses on businesses with the potential to become market leaders through sustainable growth and operational expertise.
Accura advised EQT in connection with the transaction, and Accura also assisted EQT in the acquisition of Ellab in 2019 and assisted Ellab in its acquisitions during EQT’s ownership.